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Abstract
Introduction: Extracorporeal Life Support (ECLS) and extracorporeal membrane oxygenation (ECMO) have been 
indicated as treatment for acute respiratory and/or cardiac failure. Here we describe our first year experience of in-
hospital ECLS activity, the operative algorithm and the protocol for centralization of adult patients from district 
hospitals.
Methods: At a tertiary referral trauma center (Careggi Teaching Hospital, Florence, Italy), an ECLS program was 
developed from 2008 by the Emergency Department and Heart and Vessel Department ICUs. The ECLS team consists 
of an intensivist, a cardiac surgeon, a cardiologist and a perfusionist, all trained in ECLS technique. ECMO support was 
applied in case of severe acute respiratory distress syndrome (ARDS) not responsive to conventional treatments. The 
use of veno-arterial (V-A) ECLS for cardiac support was reserved for cases of cardiac shock refractory to standard 
treatment and cardiac arrests not responding to conventional resuscitation.
Results: A total of 21 patients were treated with ECLS during the first year of activity. Among them, 13 received ECMO 
for ARDS (5 H1N1-virus related), with a 62% survival. In one case of post-traumatic ARDS, V-A ECLS support permitted 
multiple organ donation after cerebral death was confirmed. Patients treated with V-A ECLS due to cardiogenic shock 
(N = 4) had a survival rate of 50%. No patients on V-A ECLS support after cardiac arrest survived (N = 4).
Conclusions: In our centre, an ECLS Service was instituted over a relatively limited period of time. A strict collaboration 
between different specialists can be regarded as a key feature to efficiently implement the process.
Introduction
Extracorporeal circulation support techniques have been 
proposed either for treatment of cardiac and/or pulmo-
nary failure refractory to conventional treatments in 
adult patients. The first device, which assured blood 
extracorporeal oxygenation and perfusion of isolated 
organs, was developed by von Frey and Gruber in 1885 
[1]. The first heart-lung machine was projected by Gib-
bon in 1937 in order to allow open-heart surgical opera-
tions [2]. Over the years, extracorporeal circulation 
circuit has been improved and the technique optimized, 
and it is now available for clinical practice. From a general 
point of view, two methods of support are outlined: veno-
venous extracorporeal oxygenation, commonly known as 
ECMO, Extracorporeal Membrane Oxygenation, for 
respiratory function substitution and extracorporeal life 
support technique (ECLS) with a veno-arterial circula-
tion for both oxygenation and hemodynamic assistance. 
The major indications for ECMO, in adult patients, are 
severe acute respiratory distress syndrome (ARDS) 
refractory to conventional treatments [3,4], and, in 
selected cases, post-traumatic respiratory failure, severe 
asthma [5,6], and chronic lung disease waiting for lung 
transplantation [7,8].
The indications for ECLS and cardiac support are cardiac 
failure due to any cause, and cardiac arrest not responsive 
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the in-hospital mortality rate is still high (between 33% 
and 38%) and ECLS represents a rescue-therapy useful 
for refractory patients [9]. In case of in-hospital cardiac 
arrest, when ECLS was used after ten minutes of unsuc-
cessful cardiopulmonary resuscitation, an increase in sur-
vival rate at ICU discharge, at 30-day and at 1-year 
survival was reported [10].
At a tertiary referral trauma center (Careggi Teaching 
Hospital, Florence, Italy) an ECLS program was devel-
oped beginning April 2008 by the Intensive Care Unit of 
Emergency Department in association with the Intensive 
Cardiac Coronary Unit of Heart and Vessel Department. 
Here we describe our experience in implementing a mul-
tidisciplinary ECLS team for cardiac and respiratory fail-
ure. In addition to reporting our clinical experience, we 
present the algorithm for ECLS activation for in-hospital 
cardiac arrest and the experience of a national referral 
center for treatment of H1N1 influenza related respira-
tory failure.
Methods
ECLS Team
The ECLS team consists of an intensivist, a cardiac sur-
geon, a cardiologist and a perfusionist, all trained on 
ECLS technique and management. According to our acti-
vation protocol, ECLS team can be summoned within 
one hour, with 24 hour coverage.
In most cases, the intensivist primes the process on the 
basis of clinical and radiological findings and activates the 
full ECLS team. The cardiologist's main task is to evaluate 
cardiac function in the pre-ECLS phase and guides the 
correct positioning of ECLS cannulas by transesophageal 
ultrasonography. Furthermore, the cardiologist is directly 
involved in selecting patients with cardiac failure suitable 
for ECLS treatment. The cardiac surgeon, in addition to 
actively participating to the clinical decision making pro-
cess, is responsible for selecting and inserting the cannu-
las and starting the extracorporeal circulation, with the 
assistance of the perfusionist.
In case of an ECLS run, irrespectively of the unit where 
the patient was admitted (General or Cardiac ICU), all 
the professionals of the team were available for consulta-
tion and performed at least one daily evaluation.
This study, supported by institutional funds only, fol-
lowed the principles of the Helsinki declaration and was 
approved by the Internal Review Board. Informed con-
sent for data publication was obtained.
ECLS for respiratory failure
Veno-venous ECLS treatment (ECMO) was applied in 
case of severe ARDS not responsive to conventional 
treatments, but potentially reversible. Conditions of 
severe hypoxia or hypercapnia, where the limits of a pro-
tective ventilation strategy could not be maintained (tidal 
volume less than 6 mL/Kg of predicted body weight and 
plateau pressure less than 30 cmH2O), were the indica-
tions for starting extracorporeal circulation [11].
The Careggi Teaching Hospital had started a collabora-
tion with the ICUs of 12 district hospitals in Tuscany in a 
pilot project for centralization of acute lung injury/ARDS 
patients who require (or may require) ECLS treatment. In 
2008 and spring 2009, preliminary meetings were orga-
nized to inform the peripheral hospitals' ICU staff and 
Administrations about the availability of the new ECLS 
program. During the H1N1 influenza A pandemic, the 
knowledge of ECMO treatment rapidly spread among the 
medical community and the Regional Ministry of Health 
issued indications to transfer all patients affected by 
severe respiratory failure related to influenza to Careggi 
Hospital. In Appendix 1 is reported the set of parameters 
that were adopted to quickly detect patients suitable for 
extracorporeal treatment in the peripheral hospitals.
Patients deemed suitable for ECMO treatment were eval-
uated on site by the ECMO team. Depending on clinical 
condition, the transfer was performed on conventional 
ventilation or, alternatively, ECLS treatment was initiated 
in the peripheral hospital and maintained during trans-
portation [12].
We preferentially adopted a high flow technique (5-6 
litres per minute of blood flow), to maximize the oppor-
tunity of providing protective ventilation, aiming to 
achieve a plateau pressure below 28 cm H2O and PEEP 2 
cmH2O above the lower inflection point of the quasi-
static pressure volume curve, regardless the delivered 
tidal volume (in any case less than 6 ml/kg). Controlled 
respiratory frequency was reduced to 4-10/min to main-
tain normocapnia. Inspired oxygen fraction was reduced 
to 0.5 or lower, whenever possible. A recruitment 
manoeuvre was performed at least once a day, and venti-
lation with an intermittent high pressure breath ("sigh") 
was adopted to improve lung aeration [13]. During 
ECMO, nitric oxide administration [14], vasoactive sup-
port, and prone positioning were maintained or initiated 
according to clinical conditions.
ECLS for hemodynamic support
The use of ECLS for cardiac support was reserved for 
cases of cardiac shock refractory to standard treatments 
and cardiac arrests not responding to conventional resus-
citation. According to our internal protocol, ECLS was 
adopted also as a bridge to implantation of Left Ventricu-
lar Assist Device or to heart transplantation [15].
ECLS was employed in cases of in-hospital cardiac arrest 
when the patient was considered to have a good chance of 
recovery both for clinical conditions and for the timing of 
resuscitation. An age limit of seventy years, severe irre-
versible brain damage, terminal malignancy, pre-signed 
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tions to prolonged systemic heparin infusion were the 
only strict exclusion criteria taken into account. In case of 
cardiac arrest, hypothermia was rapidly initiated and was 
maintained for 24 hours at a temperature between 32-
34°C [16].
Veno-arterial (V-A) ECLS treatment was considered con-
traindicated, when a severe aortic incompetence, aortic 
dissection or ventricular thrombosis was detected by 
echocardiography.
Equipment
The ECLS circuit consisted of a Rotaflow Maquet Cen-
trifugal Pump (Maquet, Rastatt, Germany) and a hollow 
fiber membrane oxygenator (Quadrox-D Oxygenator, 
Maquet, Rastatt, Germany), connected with biocoated 
tubes. In the V-A circuit, blood was drained through fem-
oral vein and reinfused into aorta through femoral artery. 
For V-V ECLS two types of cannulas were used. At the 
beginning, Raumedic cannulas ranging from 21 to 28 
french (Raumedic AG, Germany) were employed with 
femoral and jugular vein cannulation. Since July 2009, 
Avalon Elite™ Bi-Caval Dual Lumen Catheters have 
become available. These specially designed dual lumen 
cannulas, inserted in the right internal jugular vein, per-
mit both drainage and reinfusion of blood. In V-A ECLS, 
the distal perfusion of the limb could be jeopardized by 
the relatively large bore inflow cannula, inserted in the 
femoral artery at the groin: to prevent leg ischemia, we 
usually inserted a small shunt cannula (14 french) in the 
femoral artery, distally to the ECLS cannula. Heparin 
therapy was titrated by bedside measurement of activated 
partial thromboplastin time (aPTT) with Hemochron 
(Hemochron Jr. Sign. plus, ITC Europe, Milan, IT) every 
two hours.
Numerical data were summarised as median and inter-
quartile range.
Results
A total of 21 patients were treated with ECLS during the 
first one year of activity (April 2008 - December 2009). 
Among them, 13 were treated with ECMO for respiratory 
failure (Table 1), and 8 were treated with V-A ECLS due 
to cardiac arrest (Table 2) and cardiogenic shock (Table 
3). The most frequent complication observed was local 
bleeding from the insertion points of the cannulae, cen-
tral line access site and tracheostomy (36%). In one case, 
oxygenator failure occurred due to clots formation; in this 
occasion a rapid increase of D-Dimers was observed, fol-
lowed by a worsening of oxygenation and decarboxyla-
tion performance of the artificial lung. Circuit change 
was promptly carried out with no further complications. 
In one case of V-A ECLS, major bleeding occurred at site 
of cannulae insertion several days after successful wean-
ing, requiring multiple transfusions. At surgical inspec-
tion a femoral artery wall lesion was found and required 
prosthetic repair.
Five patients received renal replacement therapy (contin-
uous veno-venous hemofiltration, CVVH). The CVVH 
was connected in-line to the extracorporeal circuit with 
the withdrawal line before oxygenator and return line 
after the oxygenator. Renal function recovered in all 
cases, and both ECLS and CVVH run was uneventful on 
this configuration.
During extracorporeal support, invasive procedures were 
carried out without any immediate complications. 
Among these, four bedside percutaneous tracheotomies 
(Ciaglia technique) were performed, and two narrow bore 
pleural catheters were inserted under ultrasound guid-
ance for massive pleural effusions. Autopsy was per-
formed in all non surviving patients and no lesion of 
vessels due to the presence of cannulae was observed.
ECMO for respiratory failure
A total of 13 patients were treated with ECMO for ARDS: 
six patients were affected by bacterial pneumonia, five 
patients had H1N1-related ARDS (two with Legionella 
Pneumophila superinfection), and 2 patients presented 
trauma-related respiratory failure. Data of each patient 
are represented in Table 1. Median age was 59 years (IQR 
44-65), with a prevalence of male sex (85%). Median ICU 
length of stay was 17 days (IQR 13-20). Eight out of 13 
patients were successfully weaned from ECMO and dis-
charged from ICU (overall survival rate of 62%). All 
H1N1 patients were discharged from ICU and from hos-
pital.
The median duration of ECMO was 235 hours (IQR 151-
269), with a difference between survivors (221 hours) and 
non survivors (257 hours). We considered time from veri-
fication of ECMO criteria to extracorporeal support start 
as an efficiency parameter ("time to ECMO"), and it was 6 
hours (IQR 4-9).
From October 2009, when our ECMO Service became 
the referral centre of Central Italy for H1N1-induced 
ARDS, extracorporeal support was initiated in the 
peripheral hospital in 3 cases. Inter-hospital transport 
was safely performed on extracorporeal support and all 
patients were discharged alive from ICU.
One young patient (19 years) died due to severe traumatic 
brain injury. In this patient, ECMO was maintained in the 
first 12 hours without systemic heparin infusion and no 
complications occurred during extracorporeal treatment. 
After cerebral death confirmation, multiple organ dona-
tion was accomplished. One patient (a 64 year-old 
woman) died due to subarachnoidal hemorrhage, 
although coagulation parameters were normal.
 ECMO-related 
complications
ICU LOS 
(days)
ICU 
outcome
Local bleeding 33 Survived
None 3 Non survived
Intracranial 
bleeding
3 Non survived
Local bleeding 65 Survived
Local bleeding 20 Survived
Local bleeding 12 Non survived
Oxygenator 
failure
27 Non 
survived
None 15 Non 
survived
None 17 Survived
None 13 Survivedl .  
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Table 1: Patients treated with ECMO for respiratory failure.
Patients Age/Gender SAPS II at 
admission
Indication Time to ECMO 
from ARDS 
diagnosis (days)
Hours of critical hypoxia 
(PaO2/FiO2 < 60) and/or 
critical acidosis 
(pH < 7.20)
ECMO duration
(hours)
Pt 1 70/M 27 ARDS
(infective)
12 4 269
Pt 2 19/M 47 ARDS
(post-traumatic)
1 4 33
Pt 3 64/F 62 ARDS
(infective)
1 2 44
Pt 4 65/M 58 ARDS
(post-traumatic)
1 1 231
Pt 5 69/M 29 ARDS
(infective)
1 5 264
Pt 6 67/M 82 ARDS
(infective)
10 8 253
Pt 7 59/M 50 ARDS
(infective)
4 8 626
Pt 8 61/M 62 ARDS
(infective)
5 5 330
Pt 9 15/M 66 ARDS
(H1N1)
0 5 137
Pt 10 58/M 24 ARDS
(H1N1)
2 4 154P e
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2 Pt 11 44/F 46 Viral acute 
lung failure
(H1N1)
2 5 374 Local bleeding 20 Survived
/M 40 ARDS
(H1N1)
1 6 184 Local bleeding 17 Survived
/M 44 Viral acute 
lung failure
(H1N1)
1 6 151 None 18 Survived
eated with ECMO for respiratory failure. (Continued)
eated with V-A ECLS for in-hospital cardiac arrest.
/Gender SAPS II at 
admission
Diagnosis at 
hospital 
admission
Cardiac arrest 
etiology
Initial rhythm 
of cardiac 
arrest
ACLS 
duration to 
ECLS 
(minutes)
Return of 
Spontaneous 
Circulation 
(ROSC)
ECLS duration 
(hours)
ECLS-related 
complications
ICU LOS 
(days)
ICU outcome
66/F 60 Septic shock Multi Organ 
Dysfunction 
Syndrome
Asystole 60 No 6 None 2 Non survived
59/M 69 Cardiac arrest Bridge to 
diagnosis
Pulseless 
electrical 
activity
90 Yes 25 None 2 Non survived
16/M 40 Trauma with 
brain injury
Trauma Pulseless 
electrical 
activity
45 No 46 None 9 Non survived
23/M 80 Trauma Hemorrhagic 
shock
Pulseless 
electrical 
activity
55 No 3 None 1 Non survivedl .  
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Pt 12 48
Pt 13 30
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Four victims of intra-hospital cardiac arrest received V-A 
ECLS for cardiac support (Table 2). Patients were 41 
years old (median, IQR 21-61; male sex 75%). The median 
duration of advanced cardiac life support manoeuvres 
before ECLS start was 58 minutes (IQR 53-68), and the 
median duration of ECLS was 16 hours (5-30). In two 
patients, the ECLS support started in the Emergency 
Room. All four patients died during their ICU stay (one 
patient after ECLS withdrawal).
Data of the four patients treated for cardiogenic shock are 
represented in Table 3. Median age was 49 years (IQR 38-
58, male sex 50%). Among them, 2 patients survived and 
were discharged from ICU. In these patients, median 
duration of ECLS was 96 hours (IQR 60-137). Intraaortic 
balloon pump was necessary in all four patients. Survival 
rate was 50%.
Discussion
From the experience here reported, we can state that, 
with a close cooperation between different specialists 
(intensivist, cardiologist, cardiac surgeon, nurse, perfu-
sionist), an ECLS Service can be started over a relatively 
limited period of time, achieving a high level of efficiency. 
Our model of ECLS team has allowed us to start extracor-
poreal support in different hospital scenarios, such as 
ICU and Emergency Room. This feature of flexibility and 
adaptability of our ECMO system has made it particularly 
beneficial during the Influenza A pandemic, making this 
resource available also in peripheral hospitals.
The management of a patient on ECLS is still challenging 
in terms of utilization of resources and commitment of 
health personnel. Beyond the insertion procedure, a mul-
tidisciplinary team can better accomplish the tasks of 
daily management of the patient, as an intensivist, a car-
diac surgeon and a perfusionist should repeatedly evalu-
ate the circuit and the patient to guarantee a safe and 
uneventful treatment. Furthermore, every ECLS patient 
needs a dedicated nurse. With the assistance of these 
dedicated professionals, also in-hospital transportation 
can be safely carried out (i.e. to radiological suite). In our 
population 63% of patients received a CT scan during 
ECLS treatment, and no transport-related complications 
occurred. The most common complication was local 
bleeding, usually simple to manage. In this regard, the use 
of Bioline surface-heparinized circuits allowed a limited 
dose of heparin, and may have reduced the incidence of 
complications such as coagulation, complement activa-
tion, thrombus formation and the need for transfusions 
[17-19].
The survival rate of 62% of our patients treated with 
ECMO for respiratory failure is comparable to other pub-
lished studies. In 2004, Hemmila and co-workers retro-
spectively reviewed 255 patients with ARDS treated with 
ECMO between 1989 and 2004, showing a 67% of 
patients successfully weaned from ECMO and a hospital 
discharge of 52% [20]. More recently, the CESAR (Con-
ventional ventilation or ECMO for Severe Adult Respira-
tory Failure) trial has shown an increase of survival rate, 
without severe disability, 6 months after randomization 
Table 3: Patients treated with V-A ECLS in case of cardiogenic shock.
Patients Age/Gender SAPS II at 
admission
Cardiogenic 
shock etiology
Intra Aortic 
Balloon Pump
ECLS duration 
(hours)
ECLS-related 
complications
ICU LOS 
(days)
ICU outcome
Pt 1 43/M 61 Post cardiac 
arrest heart 
failure-ARDS in 
near-drowning
Yes 120 None 26 Survived
Pt 2 55/F 67 Multi Organ 
Dysfunction 
Syndrome
No 72 None 5 Non survived
Pt 3 68/M 91 Multi Organ 
Dysfunction 
Syndrome
No 24 None 2 Non survived
Pt 4 24/F 47 Post cardiac 
arrest heart 
failure
Yes 189 Local 
bleeding, 
aneurysm
14 Survived
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tional ventilation (63% vs 47%) [4].
From the first phase of implementation, our service was 
conceived to provide extracorporeal support even in 
peripheral institutions, therefore a dedicated ambulance 
was specifically prepared and all equipment arranged for 
transportation. In our opinion, this is a key feature for an 
effective ECMO service as inter-hospital transportation 
of patients with severe respiratory failure can be challeng-
ing due to the fact that limited possibilities of interven-
tion are available and clinical deterioration may occur 
[21]. Therefore, several centres recommend the start of 
extracorporeal assistance before transfer [22,12]. In our 
out-of-hospital ECMO experience, one patient was safety 
transferred by ambulance from a distance of 400 Km.
We report quite a short time to establish V-A ECLS in 
case of in-hospital cardiac arrest (58 min). Furthermore, 
there is a trend towards a progressive reduction of this 
interval over time. Despite this remarkable performance 
of our ECLS system in terms of speed of response, no 
patient receiving extracorporeal support for cardiac 
arrest survived. In a large series of patients on extracor-
poreal support for in hospital cardiac arrest, Jaski and co-
workers reported a long term survival rate of 23% in wit-
nessed events and no survival in non-witnessed arrest. At 
multivariate analysis cardiac arrest in the critical care 
unit was found to be the only independent variable pre-
dictive of outcome [23]. In another series of 40 in-hospi-
tal cardiac arrest victims, time before ECLS was 105 
minutes, and 20% survival rate was reported [24]. In our 
experience, the number of cardiac arrest patients with 
ECLS is so limited that comparison to published data is 
not feasible. Nevertheless, the reason for not responding 
to V-A ECLS treatment in our cases might be possibly 
related to the severity of previous clinical condition (2 
traumas, 1 septic shock) and to the underling organ dys-
function.
Conclusions
ECMO and V-A ECLS might be considered a therapeutic 
option in patients with severe ARDS and/or with cardiac 
failure or cardiac arrest. In our experience, a well-timed 
start of ECMO in case of ARDS, prevents the progression 
of ventilator-induced lung injury and increases the 
chances of lung recovery. Also in case of cardiogenic 
shock, an extracorporeal technique seems a viable option 
and increases the possibility of early cardiac recovery 
avoiding neurological damages and multi-organ failure. 
To guarantee a safe treatment, the involvement of several 
properly trained physicians and nurses seems advisable.
Key messages
• An ECLS Service can be effectively organized in a Cen-
ter were the needed competencies are available (intensiv-
ist, cardiologist, cardiac surgeon).
• When physicians and nurses are skilled in the tech-
nique, the Service can provide a safe transfer of critically 
ill patients from remote hospitals.
• ECMO should be considered in the initial phase of 
ARDS, when failure to ventilation strategy occurs.
• The resource of ECMO has resulted to be particularly 
important in the event of cases of severe respiratory fail-
ure, as in the last pandemic of Influenza A.
Appendix 1: First contact criteria to discuss the 
need of ECLS
The parameter are referred to a condition of lung protec-
tive ventilation's (tidal volume:4-6 ml/Kg of predicted 
body weight; plateau pressure ≤ 30 cmH2O; PEEP > lower 
inflection point of the curve pressure-volume).
PEEP: positive end-expiratory pressure; PaO2: arterial 
oxygen partial pressure; FiO2: inspired oxygen fraction; 
RR: respiratory rate; SaO2: peripheral oxygen saturation; 
SvO2: central venous oxygen saturation.
Acute respiratory failure with 1 of the following condi-
tion:
1. SaO2 < 85% for at least 1 hour
2. Oxygenation Index1 >25 for at least 6 hours after venti-
lation's optimization
3. PaO2/FiO2 < 100 with PEEP ≥ 10 cmH2O for at least 6 
hours after ventilation's optimization
4. Hypercarbia with pH < 7.25
5. SvO2 < 65% with hematocrit >30 and under vasoactive 
drugs infusion
1Mean airway pressure (cmH2O) * FiO2 * 100/PaO2
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